GLAXF - GSK Breathes New Life Into Asthma Treatment With Depemokimab

2024-05-22 11:19:16 ET

Summary

• GSK plc has advanced asthma care with their innovative depemokimab therapy, which is an IL-5 inhibitor and offers a long-acting option for severe asthma.
• Depemokimab demonstrated a significant reduction in asthma exacerbations over 52 weeks in clinical trials.
• Financially, GSK shows solid earnings growth but has a current ratio below 1, indicating possible liquidity issues.
• Recommend investing in GSK given its robust pipeline, reasonable debt, and strong operational performance.

GSK Advances Asthma Care with Innovative Depemokimab Therapy

My last article on GSK plc ( GSK ) highlighted their venture into the RSV treatment landscape with Arexvy, the first approved RSV vaccine for older adults. Arexvy inspired a robust Q3 '23 earnings report . I recommended a buy on GSK, and its stock has risen 29.5% versus S&P 500 (SP500) returns of 22.7%. Yesterday, the company revealed late-stage data for their asthma therapy, depemokimab. GSK may have another blockbuster on their hands....

For further details see: